What can Digital Health do in Oncology?
For many years, cancer has been one of the largest and most significant categories of disease around the world. In 2020, 18.1 million new cases of cancer were diagnosed worldwide. In Spain alone, it is estimated that there could be 286,664 cases in 2024, according to data from REDECAN (the Spanish Cancer Registry Network).
Digital Health in Heart Failure: Optimizing results with fewer resources
Heart Failure is considered by many experts to be a true epidemic. On a global level, it affects 64 million people, and according to the Spanish Heart Foundation 770,000 people have been diagnosed in Spain. It is a multifactorial disease with a high prevalence of comorbidities, which makes this condition difficult to manage and monitor.
How are Digital Therapeutics (DTx) making headway in the Spanish Health System?
Digital Therapeutics (DTx) (software that has been clinically validated and supported with scientific evidence used to prevent, manage, and treat diseases), have been increasingly adopted around the world, enabling the development of new patient-centered healthcare models focused on the efficiency and sustainability of the system.
Persei vivarium obtains ISO 13485 certification, accrediting quality management systems for medical devices
After a complete and exhaustive auditing process, our company, Persei vivarium, has obtained the ISO 13485 certification that accredits the organization’s quality management system for the design, development, and commercialization of medical device software.
Persei vivarium receives funding from CDTI for R&D projects
Our company, Persei vivarium, has become a beneficiary of funding from CDTI for R&D projects. The Center for Technological Development and Innovation (CDTI) is a public business entity under the authority of the Spanish Ministry of Science, Innovation, and Universities, charged with promoting innovation and technological development in Spanish businesses.
Successful expansion of the National Sacral Neuromodulation Registry driven by the “Spanish Society of Coloproctology” (AECP)
The National Sacral Neuromodulation Registry was launched in January 2023 as an observational study sponsored by the AECP, focused on patients with proctological pelvic dysfunctions, including fecal incontinence, who have received implanted sacral neuromodulation therapy (NMS).